Corrigendum to “Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective and Potent Allosteric TYK2 Inhibitor” Journal of Investigative Dermatology, Volume 146, Issue 1, January 2026, Pages 214-222.e7

Shailly Mehrotra, Yasuyo Sano, Petro Halkowycz, Elizabeth Wilson, Chandra Durairaj, Kok-Fai Kong, Guliang Xia, Faith Dunbar, Taylor Spector, Graham A. Heap, Christopher G. Bunick, Iain B. McInnes

Open source

DOI: 10.1016/j.jid.2026.07.008
Published: 2026-09
Container: Journal of Investigative Dermatology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jid.2026.07.008,
  title = {Corrigendum to “Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective and Potent Allosteric TYK2 Inhibitor” Journal of Investigative Dermatology, Volume 146, Issue 1, January 2026, Pages 214-222.e7},
  author = {Shailly Mehrotra and Yasuyo Sano and Petro Halkowycz and Elizabeth Wilson and Chandra Durairaj and Kok-Fai Kong and Guliang Xia and Faith Dunbar and Taylor Spector and Graham A. Heap and Christopher G. Bunick and Iain B. McInnes},
  year = {2026},
  journal = {Journal of Investigative Dermatology},
  doi = {10.1016/j.jid.2026.07.008},
  url = {https://doi.org/10.1016/j.jid.2026.07.008}
}

RIS

TY  - JOUR
TI  - Corrigendum to “Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective and Potent Allosteric TYK2 Inhibitor” Journal of Investigative Dermatology, Volume 146, Issue 1, January 2026, Pages 214-222.e7
AU  - Shailly Mehrotra
AU  - Yasuyo Sano
AU  - Petro Halkowycz
AU  - Elizabeth Wilson
AU  - Chandra Durairaj
AU  - Kok-Fai Kong
AU  - Guliang Xia
AU  - Faith Dunbar
AU  - Taylor Spector
AU  - Graham A. Heap
AU  - Christopher G. Bunick
AU  - Iain B. McInnes
PY  - 2026
JO  - Journal of Investigative Dermatology
DO  - 10.1016/j.jid.2026.07.008
UR  - https://doi.org/10.1016/j.jid.2026.07.008
ER  -

APA

Mehrotra, S., Sano, Y., Halkowycz, P., Wilson, E., Durairaj, C., Kong, K., Xia, G., Dunbar, F., Spector, T., Heap, G. A., Bunick, C. G., & McInnes, I. B. (2026). Corrigendum to “Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective and Potent Allosteric TYK2 Inhibitor” Journal of Investigative Dermatology, Volume 146, Issue 1, January 2026, Pages 214-222.e7. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2026.07.008

Source records

crossref · retrieved 2026-09-26T23:32:15.708Z